Vivet will be attending and presenting during 6th annual Gene Therapy for Rare Disorders Europe in London.
“Gain European Regulatory Clarity to Progress Efficient & Robust Gene Therapies for Rare Disease” is this year’s theme.
Vivet Therapeutic’s Chief Development Officer, Anne Douar, will participate to 2 sessions:
👉 Anne will talk about “Developing a Strategy for Re-Administration of AAV Gene Therapies Exploring dosing strategies” during the Clinical Trials & Tribulations section (Wednesday Oct. 26 – 12pm)
👉 She will also participate in the following panel: “The Challenges Associated With Scaling-Up to Commercial Manufacturing” during the CMC Challenges section (Wednesday Oct. 26 – 11am)